# Oncobiologics financial performance and insider trading

> Live situation record from CLSTR: https://clstr.news/situations/oncobiologics-financial-performance-and-insider-trading
> Updated: 2026-08-15T00:11:19.000Z. Sources: 2. Developments: 2.

Oncobiologics, Inc. has experienced significant insider trading activity alongside fluctuating financial performance. In late July, Director Faisal Ghiath Sukhtian purchased 95,398 shares at an average price of $1.05 per share.

By mid-August, Oncobiologics reported quarterly earnings that missed analyst expectations, posting earnings per share of ($0.09) against an estimated ($0.08) and revenue of $0.01 million against an estimated $0.97 million. Despite this miss, Director Sukhtian significantly increased his position on August 12th by purchasing 2,525,252 shares at an average cost of $0.99 per share, a transaction valued at approximately $2.5 million. Additionally, Goldman Sachs Group Inc. increased its position in the company by 74.1% during the first quarter.

## Timeline

### 2026-08-15: Oncobiologics reports quarterly earnings miss and director stock purchase

Oncobiologics (NASDAQ:OTLK) reported quarterly earnings of ($0.09) per share, missing estimates, while Director Ghiath Sukhtian purchased over 2.5 million shares.

2 sources. https://clstr.news/cluster/oncobiologics-reports-quarterly-earnings-miss-and-director-stock-purchase

### 2026-07-28: Oncobiologics and Aktis Oncology Directors Trade Shares

Oncobiologics director Faisal Ghiath Sukhtian bought 95,398 shares; Aktis Oncology director Ken Herrmann sold 4,856 shares, affecting their holdings.

2 sources. https://clstr.news/cluster/oncobiologics-and-aktis-oncology-directors-trade-shares

---
Cite as: Oncobiologics financial performance and insider trading. CLSTR, https://clstr.news/situations/oncobiologics-financial-performance-and-insider-trading